Does levetiracetam cause fatigue in a patient who has been seizure‑free for one year after provoked seizures following cardiac surgery?

Does Levetiracetam Cause Fatigue?

Yes, levetiracetam definitively causes fatigue and asthenia as recognized adverse effects, occurring in approximately 15-27% of patients, which is significantly higher than placebo. This is well-established in FDA labeling and confirmed across multiple evidence sources.

Evidence from FDA Drug Labeling

The FDA label explicitly identifies asthenia (weakness/fatigue) as one of the five most frequent adverse events with levetiracetam 1. In controlled trials of adults with partial onset seizures:

• 14.7% of levetiracetam-treated patients reported asthenia versus 9.1% on placebo
• Fatigue occurred in 27.3% of patients in open-label studies at doses up to 3000 mg/day 2
• 0.8% discontinued treatment due to asthenia (compared to 0.5% on placebo)
• Dose reduction was required in 0.5% of treated patients 1

The FDA label notes that asthenia and somnolence occurred most frequently within the first 4 weeks of treatment 1.

Meta-Analysis Confirmation

A 2026 systematic review and meta-analysis provides the strongest recent evidence: levetiracetam-treated patients demonstrated significantly higher risk of asthenia/fatigue compared with placebo (OR 1.48,95% CI: 1.04-2.11) 3. This analysis included 7 randomized controlled trials comparing levetiracetam to placebo.

Dose-Related Considerations

Fatigue appears dose-dependent for levetiracetam 4:

• A 2021 study found that levetiracetam doses significantly correlated with Fatigue Severity Scale scores (p = 0.023)
• Higher doses (3000-4000 mg/day) are associated with increased fatigue reports
• Approximately 52% of epilepsy patients on antiepileptic monotherapy reported clinically significant fatigue (FSS score ≥4) 4

Clinical Context for Your Patient

For a patient seizure-free for one year after provoked seizures following cardiac surgery, this is particularly relevant because:

1. Provoked seizures have different recurrence risk than unprovoked epilepsy - many guidelines suggest shorter treatment duration or even no prophylaxis beyond the acute period for purely provoked seizures
2. If continuing levetiracetam is deemed necessary, fatigue should be monitored as a legitimate adverse effect
3. Consider dose reduction or discontinuation if seizure-free status has been maintained for one year, as the benefit-risk ratio shifts when seizures were provoked rather than from underlying epilepsy

Management Algorithm

If fatigue develops on levetiracetam:

1. Confirm timing: Most fatigue occurs within first 4 weeks but can persist 1
2. Assess dose: Consider reduction if on higher doses (>2000 mg/day) 4
3. Evaluate necessity: For provoked post-surgical seizures with 1-year seizure freedom, discuss discontinuation with neurology
4. Alternative if continuation needed: Switch to lacosamide or brivaracetam if antiseizure medication still indicated 5

Important Caveats

• Fatigue in epilepsy patients is multifactorial - seizure frequency itself correlates with fatigue independent of medication 4
• The adverse effect profile is generally mild compared to older antiepileptic drugs 6
• Somnolence (14.8%) and fatigue often co-occur, creating cumulative sedating effects 1, 3

Bottom line: Levetiracetam causes fatigue in a clinically significant proportion of patients, and for someone seizure-free for one year after provoked seizures, the risk-benefit of continuing therapy should be reassessed.